> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Proposal to Withdraw 4 NDAs
- URL: https://www.fdaweb.com/proposal-to-withdraw-4-ndas/
- Published: 2019-11-15T12:00:00.000Z
- Updated: 2026-09-14T15:53:22.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145513

*Federal Register* notice: FDA is proposing to withdraw approval of four NDAs from multiple NDA holders because they have repeatedly failed to file required annual reports. The NDAs are:  

- NDA 014217 Maolate (chlorphenesin carbamate) tablets, 400mg (Pan American Laboratories)
- NDA 018663 Chymodiactin (chymopapain) for Injection, 4,000 Units/vial and 10,000 Units/vial (Chart Medical)
- NDA 020530 Iontocaine (epinephrine and lidocaine hydrochloride (HCl)) Topical Solution, 01 mg/milliliter; 2% (Iomed)
- NDA 021504 Lidosite Topical System: LidoSite Patch (lidocaine HCl and epinephrine topical iontophoretic patch) 10%/0.1% and LidoSite Controller (Vyteris)

To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-24921.pdf?ref=fdaweb.com).